CF PHARMTECH (02652): The company's leading new inhalable nucleic acid drug development project has been selected as part of the Jiangsu Province Science and Technology Major Project "Innovative Biopharmaceuticals" for 2025.

CF PHARMTECH (02652) announced that the company-led new inhalable nucleic acid drug development project has recently been selected as a major technology project for innovative biopharmaceuticals in Jiangsu Province in 2025. The project focuses on the key challenges in delivering small nucleic acids (siRNA) drugs to the lungs and aims to advance the translation research and preclinical development of inhalable nucleic acid candidate drugs. The project plans to support the development of inhalable nucleic acid candidate drugs for major respiratory diseases (including asthma, chronic obstructive pulmonary disease, and pulmonary fibrosis). The scope of work includes optimizing delivery systems, pharmaceutical and process development, preclinical research, and preparation for new drug clinical trial applications. The company believes that the selection of this project is of strategic importance to the group and further validates the strength of the group's technology platform. Delivery technology is a key barrier to siRNA lung therapy. To address this, the company has independently developed an efficient lung-targeted delivery system, and related candidate drugs have shown promising therapeutic potential in preclinical studies. The selection of this project reflects the full recognition of the company's and its collaborative partners' joint research and development capabilities in the forefront of delivery technology by relevant departments and expert reviewers. The company will continue to strive to provide more valuable treatment options for patients and create sustainable long-term returns for shareholders through technological innovation.